Hyperbaric-Oxygen Therapy Improves Survival and Functional Outcome of Acute Severe Intracerebral Hemorrhage
Copyright © 2018 IMSS. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Prognosis of spontaneous intracerebral hemorrhage (ICH) remains poor worldwide.
AIMS OF THE STUDY: To investigate the effect and optimal protocol for hyperbaric-oxygen therapy (HBOT), and reduce incidence of upper gastrointestinal bleeding (UGIB) in ICH.
METHODS: This prospective, randomized, controlled trial included 565 patients with acute severe ICH. Participants were randomly assigned to a sham-control group (Group A) and four intervention groups: Groups B and C with 2.0 atmospheres absolute (ATA) pressure and HBOT exposure for 60 or 90 sessions, respectively; and Groups D and E with 1.5 ATA for 60 or 90 sessions, respectively. All patients received emergency craniotomy with hematoma evacuation. Outcome measures were modified Barthel Index (MBI) and modified Rankin Scale (mRS) scores, mortality rates at follow-up six months. UGIB rates were assessed as potential side effect.
RESULTS: In four intervention groups, MBI and mRS scores were all significantly improved, and mortality rates were all significantly decreased compared with Group A (all p < 0.005). UGIB rates were 39.25, 60.00, 64.49, 36.79, and 34.26% in Groups A, B, C, D, and E, respectively. UGIB rates in Groups B and C were significantly increased compared with Groups A, D and E (all p < 0.005). None of UGIB were clinically significant.
CONCLUSIONS: HBOT significantly improves survival and functional outcomes of ICH. HBOT at 1.5 and 2.0 ATA had the same beneficial effect. A pressure of 1.5 ATA and 60 HBOT exposures represents an optimal protocol for HBOT. Further studies are needed to optimize the protocol per specific patient.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Archives of medical research - 48(2017), 7 vom: 25. Okt., Seite 638-652 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Xiaowei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.06.2019 Date Revised 28.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arcmed.2018.03.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282046836 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282046836 | ||
| 003 | DE-627 | ||
| 005 | 20231225033027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arcmed.2018.03.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0940.xml |
| 035 | |a (DE-627)NLM282046836 | ||
| 035 | |a (NLM)29548729 | ||
| 035 | |a (PII)S0188-4409(18)30043-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Xiaowei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperbaric-Oxygen Therapy Improves Survival and Functional Outcome of Acute Severe Intracerebral Hemorrhage |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2019 | ||
| 500 | |a Date Revised 28.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 IMSS. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Prognosis of spontaneous intracerebral hemorrhage (ICH) remains poor worldwide | ||
| 520 | |a AIMS OF THE STUDY: To investigate the effect and optimal protocol for hyperbaric-oxygen therapy (HBOT), and reduce incidence of upper gastrointestinal bleeding (UGIB) in ICH | ||
| 520 | |a METHODS: This prospective, randomized, controlled trial included 565 patients with acute severe ICH. Participants were randomly assigned to a sham-control group (Group A) and four intervention groups: Groups B and C with 2.0 atmospheres absolute (ATA) pressure and HBOT exposure for 60 or 90 sessions, respectively; and Groups D and E with 1.5 ATA for 60 or 90 sessions, respectively. All patients received emergency craniotomy with hematoma evacuation. Outcome measures were modified Barthel Index (MBI) and modified Rankin Scale (mRS) scores, mortality rates at follow-up six months. UGIB rates were assessed as potential side effect | ||
| 520 | |a RESULTS: In four intervention groups, MBI and mRS scores were all significantly improved, and mortality rates were all significantly decreased compared with Group A (all p < 0.005). UGIB rates were 39.25, 60.00, 64.49, 36.79, and 34.26% in Groups A, B, C, D, and E, respectively. UGIB rates in Groups B and C were significantly increased compared with Groups A, D and E (all p < 0.005). None of UGIB were clinically significant | ||
| 520 | |a CONCLUSIONS: HBOT significantly improves survival and functional outcomes of ICH. HBOT at 1.5 and 2.0 ATA had the same beneficial effect. A pressure of 1.5 ATA and 60 HBOT exposures represents an optimal protocol for HBOT. Further studies are needed to optimize the protocol per specific patient | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Acute severe hypertensive intracerebral hemorrhage | |
| 650 | 4 | |a Basal ganglia area | |
| 650 | 4 | |a Craniotomy or decompressive craniectomy | |
| 650 | 4 | |a Evacuation of hematoma | |
| 650 | 4 | |a Hyperbaric-oxygen therapy | |
| 650 | 4 | |a Upper gastrointestinal bleeding | |
| 700 | 1 | |a Li, Jingze |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xuehui |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Zhaosheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jinrong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Wangmiao |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Shuzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Yanqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jianchao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yongqian |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Jianhui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guangjie |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenchao |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yazhao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mingzhe |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wanzeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhanyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Baoshuai |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jianhui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Gengshui |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ronghua |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xiuzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Cunling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of medical research |d 1996 |g 48(2017), 7 vom: 25. Okt., Seite 638-652 |w (DE-627)NLM012656291 |x 1873-5487 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2017 |g number:7 |g day:25 |g month:10 |g pages:638-652 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arcmed.2018.03.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2017 |e 7 |b 25 |c 10 |h 638-652 | ||